Galecto has filed to go public nine years after being founded in Sweden to commercialise research from Lund and Edinburgh universities.

Galecto, a US-based fibrosis and cancer therapy developer advancing research originating from Lund and Edinburgh universities, has filed to raise up to $100m initial public offering. Founded in 2011 in Sweden, Galecto is working on small molecule therapeutics for diseases such as cancer and fibrosis, a condition where connective tissue becomes scarred. The IPO proceeds…

The rest of this content is only accessible to Global University Venturing Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.